Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.99 USD | +0.20% | -8.94% | -11.68% |
09/05 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
08/05 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.68% | 34Cr | |
+43.36% | 5.81TCr | |
-5.31% | 4.05TCr | |
+37.52% | 3.9TCr | |
+14.75% | 2.67TCr | |
-12.56% | 2.66TCr | |
-22.45% | 1.9TCr | |
+0.04% | 1.22TCr | |
+25.12% | 1.2TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics Says US FDA Clears Investigational New Drug Application for CFT8919; Shares Rise Pre-Bell